08:54 AM EST, 12/31/2024 (MT Newswires) -- Cocrystal Pharma ( COCP ) said Tuesday it plans to extend enrollment in a phase 2a influenza challenge study due to low influenza infection among study participants, making virology results uninterpretable.

The study evaluating Cocrystal's investigational inhibitor CC-42344 has shown no serious adverse events so far, the company said.

Cocrystal Pharma ( COCP ) shares were down 32% in recent premarket trading.